<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Century Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/century-therapeutics-inc</link>
<description>Latest news and press releases for Century Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/century-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683584a978dffbe2df0fd320.webp</url>
<title>Century Therapeutics, Inc.</title>
<link>https://6ix.com/company/century-therapeutics-inc</link>
</image>
<item>
<title>Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-selected-for-oral-presentation-of-cnty813-preclinical-data-at-the-american-diabetes-association-86th-scientific-sessions</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-selected-for-oral-presentation-of-cnty813-preclinical-data-at-the-american-diabetes-association-86th-scientific-sessions</guid>
<pubDate>Thu, 30 Apr 2026 20:05:00 GMT</pubDate>
<description>CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the Ame</description>
</item>
<item>
<title>Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-full-year-2025-financial-results-and-business-updates-1</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-full-year-2025-financial-results-and-business-updates-1</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND</description>
</item>
<item>
<title>Century Therapeutics to Participate in Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-to-participate-in-upcoming-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-to-participate-in-upcoming-investor-conferences-in-march</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent</description>
</item>
<item>
<title>Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-secures-oversubscribed-135-130000161</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-secures-oversubscribed-135-130000161</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The financing is being led by new investor TCGX, an</description>
</item>
<item>
<title>Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-appoints-accomplished-biotechnology-130000262</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-appoints-accomplished-biotechnology-130000262</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Co</description>
</item>
<item>
<title>Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-participate-piper-sandler-210100265</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-participate-piper-sandler-210100265</guid>
<pubDate>Tue, 25 Nov 2025 21:01:00 GMT</pubDate>
<description>PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows: Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will participate in the “State of the Art in Cell Therapy” panel</description>
</item>
<item>
<title>Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-third-quarter-123000477</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-third-quarter-123000477</guid>
<pubDate>Thu, 13 Nov 2025 12:30:00 GMT</pubDate>
<description>Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026Estimated cash runway into 4Q 2027 PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-</description>
</item>
<item>
<title>Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-beta-islet-120000187</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-beta-islet-120000187</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia, human C‑peptide production and mature GSIS, supported by scalable bioreactor-based manufacturingInvestigational New Drug (IND)-enabling studies on track to initiate by year-end 2025; IND submission planned as early as 2026 PHILADELPHIA, Nov. 13, 2</description>
</item>
<item>
<title>Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-present-chardan-9th-200100485</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-present-chardan-9th-200100485</guid>
<pubDate>Tue, 14 Oct 2025 20:01:00 GMT</pubDate>
<description>PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be avai</description>
</item>
<item>
<title>Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-present-h-c-120000735</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-present-h-c-120000735</guid>
<pubDate>Fri, 22 Aug 2025 12:00:00 GMT</pubDate>
<description>PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for</description>
</item>
<item>
<title>Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-second-quarter-200100001</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-second-quarter-200100001</guid>
<pubDate>Thu, 14 Aug 2025 20:01:00 GMT</pubDate>
<description>Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board ChairCash runway extended into fourth quarter 2027 PHILADELPHIA, Aug. 14, 2025 (</description>
</item>
<item>
<title>Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-two-upcoming-200100302</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-two-upcoming-200100302</guid>
<pubDate>Wed, 28 May 2025 20:01:00 GMT</pubDate>
<description>PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting</description>
</item>
<item>
<title>Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-first-quarter-200100235</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-first-quarter-200100235</guid>
<pubDate>Thu, 15 May 2025 20:01:00 GMT</pubDate>
<description>Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells and</description>
</item>
<item>
<title>Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-two-upcoming-203000403</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-two-upcoming-203000403</guid>
<pubDate>Mon, 28 Apr 2025 20:30:00 GMT</pubDate>
<description>PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations w</description>
</item>
<item>
<title>Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-host-live-fireside-200100585</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-host-live-fireside-200100585</guid>
<pubDate>Tue, 15 Apr 2025 20:01:00 GMT</pubDate>
<description>PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will</description>
</item>
<item>
<title>Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-full-2024-200100145</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-full-2024-200100145</guid>
<pubDate>Wed, 19 Mar 2025 20:01:00 GMT</pubDate>
<description>Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC),</description>
</item>
<item>
<title>Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-investigator-initiated-phase-12-trial-of-its-ipsc-derived-ink-cell-therapy-cnty-101-in-b-cell-mediated-autoimmune-diseases-sponsored-by-internationally-renowned-key-opinion-leaders</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-investigator-initiated-phase-12-trial-of-its-ipsc-derived-ink-cell-therapy-cnty-101-in-b-cell-mediated-autoimmune-diseases-sponsored-by-internationally-renowned-key-opinion-leaders</guid>
<pubDate>Tue, 21 Jan 2025 05:00:00 GMT</pubDate>
<description>- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at</description>
</item>
<item>
<title>Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-to-present-at-the-piper-sandler-36th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-to-present-at-the-piper-sandler-36th-annual-healthcare-conference</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem</description>
</item>
<item>
<title>Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-updates</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy</description>
</item>
<item>
<title>Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting</title>
<link>https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-upcoming-poster-presentations-at-the-2024-american-society-of-hematology-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/century-therapeutics-inc/news/century-therapeutics-announces-upcoming-poster-presentations-at-the-2024-american-society-of-hematology-ash-annual-meeting</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – –</description>
</item>
</channel>
</rss>